| Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases |
Globe Newswire |
01/08 |
12:00 |
| Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 |
Globe Newswire |
01/07 |
16:00 |
| Sports Sponsorship Market size to grow by USD 22.64 billion between 2022-2027 | The emergence of new sports leagues to drive the market growth - Technavio |
Globe Newswire |
01/05 |
14:00 |
| Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight |
Globe Newswire |
01/01 |
18:00 |
| Professional Women's Hockey League and Rogers Announce Strategic Partnership |
Globe Newswire |
12/29 |
20:09 |
| Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases |
Globe Newswire |
12/26 |
07:00 |
| Cartan Capital Invests in Proto Hologram |
Globe Newswire |
12/22 |
14:36 |
| Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus |
Globe Newswire |
12/21 |
12:00 |
| HotelPlanner Celebrates 20 Years Serving All Travelers |
Globe Newswire |
12/20 |
14:00 |
| TuneIn Offers Listeners the Ultimate Soundtrack for the Holiday Season with Eight New (And Free) Stations |
Globe Newswire |
12/14 |
14:30 |
| CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results |
Globe Newswire |
12/13 |
21:05 |
| RFK Sales and Marketing Team Honored with Prestigious MarCom Team Achievement Award |
Globe Newswire |
12/13 |
19:08 |
| TuneIn Partners with CountryLine Radio to Extend the Distribution of Garth Brooks? The BIG 615 Radio Station in the U.K. |
Globe Newswire |
12/13 |
12:00 |
| Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 |
Globe Newswire |
12/12 |
21:02 |
| C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma |
Globe Newswire |
12/12 |
21:01 |
| SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors |
Globe Newswire |
12/12 |
13:00 |
| Sportradar Launches ?Future of Tennis Betting? with ATP |
Globe Newswire |
12/12 |
08:00 |
| Sandman Hotel Group and GreenStep Solutions are delighted to announce their new partnership |
Globe Newswire |
12/12 |
01:00 |
| Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 |
Globe Newswire |
12/12 |
00:30 |
| Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton?s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting |
Globe Newswire |
12/11 |
17:00 |
| Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting |
Globe Newswire |
12/11 |
13:30 |
| Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes |
Globe Newswire |
12/11 |
00:30 |
| Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes |
Globe Newswire |
12/10 |
17:30 |
| Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 |
Globe Newswire |
12/10 |
01:30 |
| Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 |
Globe Newswire |
12/09 |
17:00 |
